Literature DB >> 10400003

Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function.

H W Wilmink1, J D Banga, M Hijmering, W D Erkelens, E S Stroes, T J Rabelink.   

Abstract

OBJECTIVES: The purpose of this study was to determine whether endothelial dysfunction as a consequence of direct postprandial lipid response might be favorably influenced by angiotensin-converting enzyme inhibitors or angiotensin AT1 receptor antagonists.
BACKGROUND: Postprandial triglyceride-rich lipoproteins cause endothelial dysfunction. Angiotensin-converting enzyme inhibitors have been shown to improve vascular reactivity. For angiotensin II type 1 receptor antagonists this effect is as yet uncertain.
METHODS: A randomized, double-blind, placebo-controlled crossover study in 30 healthy volunteers, aged 18 to 33 years, evaluated the effect of quinapril (40 mg daily for two weeks) and losartan (50 mg daily for two weeks) on basal as well as postprandial endothelial function measured noninvasively as percentage diameter change in the brachial artery after reactive hyperemia. Endothelium-independent dilation was measured after nitroglycerine spray sublingual.
RESULTS: An acute oral fat load impaired endothelial function. Flow-mediated vasodilation (FMD) decreased from a median of 6.2% to 4.2% (p < 0.05). There was no significant difference in preprandial endothelial function after two weeks of treatment with either quinapril or losartan compared with placebo in these healthy volunteers. Both quinapril (FMD 6.4% to 6.3%) and losartan (7.1% to 5.4%) prevented endothelial dysfunction induced by an oral fat load, although the protective effect of quinapril appeared to be more profound. The response to the endothelium-independent vasodilator nitroglycerine was unaltered throughout the study.
CONCLUSIONS: Both losartan and quinapril prevent endothelial dysfunction induced by triglyceride-rich lipoproteins in healthy volunteers. However, the protective effect of quinapril is more pronounced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400003     DOI: 10.1016/s0735-1097(99)00154-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

Review 1.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

Review 3.  Mechanism of differential effects of antihypertensive agents on serum lipids.

Authors:  R D Brook
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

4.  The postprandial state does not impair endothelial function in women with type 2 diabetes irrespective of glycaemic control.

Authors:  C H Strey; J Young; M Collier; C M Florkowski; B I Shand; R S Scott
Journal:  Diabetologia       Date:  2004-10-22       Impact factor: 10.122

5.  A single, high-fat meal adversely affects postprandial endothelial function: a systematic review and meta-analysis.

Authors:  Juanita J Fewkes; Nicole J Kellow; Stephanie F Cowan; Gary Williamson; Aimee L Dordevic
Journal:  Am J Clin Nutr       Date:  2022-09-02       Impact factor: 8.472

6.  Fat, Obesity, and the Endothelium.

Authors:  Nora Yucel; Zolt Arany
Journal:  Curr Opin Physiol       Date:  2019-09-19

Review 7.  Insulin resistance and vessel endothelial function.

Authors:  A J H H M van Oostrom; M Castro Cabezas; T J Rabelink
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

8.  Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination.

Authors:  Giuseppe Derosa; Sibilla At Salvadeo
Journal:  Integr Blood Press Control       Date:  2010-05-19

9.  A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure.

Authors:  Emile R Mohler; David Herrington; Pamela Ouyang; Charles Mangano; Susan Ritter; Pamela Davis; Das Purkayastha; Marjorie Gatlin; Robert A Vogel
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-10       Impact factor: 3.738

Review 10.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis.

Authors:  Eva Lonn
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.